References
- Johnson DA. TLR4 agonists as vaccine adjuvants – a chemist’s perspective. Expert Rev. Vaccines 12(7), 711–713 (2013).
- Ireton GC, Reed SG. Adjuvants containing natural and synthetic TLR4 ligands. Expert Rev. Vaccines 12(7), 793–807 (2013).
- Fox CB, Haensler J. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants following over 100m doses administered. Expert Rev. Vaccines 12(7), 747–758 (2013).
- Moser C, Müller M, Kaeser MD, Weydemann U, Amacker M. Influenza virosomes as vaccine adjuvant and carrier system. Expert Rev. Vaccines 12(7), 779–791 (2013).
- Darveau RP, Chilton PM. Naturally-occurring low biological reactivity LPS as vaccine adjuvants. Expert Rev. Vaccines 12(7), 707–709 (2013).
- Mount A, Koernig S, Silva A, Drane D, Maraskovsky E, Baz Morelli A. Combination of adjuvants: the future of vaccine design. Expert Rev. Vaccines 12(7), 733–746 (2013).
- Clegg CH, Rininger JA, Baldwin SL. Clinical vaccine development for H5N1 influenza. Expert Rev. Vaccines 12(7), 767–777 (2013).
- McElhaney JE, Coler RN, Baldwin SL. Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults. Expert Rev. Vaccines 12(7), 759–766 (2013).
- Vasilakos JP, Tomai MA. The use of toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Rev. Vaccines 12(7), 809–819 (2013).
- Petrovsky N. Vaccine adjuvants; in search of new paradigms. Expert Rev. Vaccines 12(7), 723–726 (2013).
- Andréassonn S. Vaccine Adjuvants; insights from industry. Expert Rev. Vaccines 12(7), 731–732 (2013).
- Rappuoli R. Vaccine adjuvants; the future is bright. Expert Rev. Vaccines 12(7), 727–729 (2013).
- Petrovsky N. Vaccine adjuvant safety: the elephant in the room. Expert Rev. Vaccines 12(7), 715–717 (2013).